In addition, DLB patients often have some degree of concomitant AD-related pathology, i.e., extracellular amyloid-β (Aβ) aggregation and intracellular tau deposition, such that up to 50% of DLB patients have a high-level AD pathology [4, 5] and approximately 25% have an AD profile in cerebrospinal fluid (CSF) [6]. Here, MAPT is linked to Alzheimer disease.